Skip to main content
Erschienen in: Journal of Bone and Mineral Metabolism 2/2016

01.03.2016 | Short Communication

Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate

verfasst von: Makoto Tanaka, Aira Matsugaki, Takuya Ishimoto, Takayoshi Nakano

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Quantitative analysis of the orientational distribution of biological apatite (BAp) crystals is proposed as a new index of bone quality. This study aimed to analyze BAp c-axis orientation in ovariectomized (OVX) monkeys treated with amino-bisphosphonates minodronic acid and alendronate as reference. Sixty female monkeys aged 9–17 years were divided into five groups: one sham group and four OVX groups. The sham group and one OVX group were treated daily with vehicle for 17 months. The other three groups were treated daily with minodronic acid at doses of 0.015 and 0.15 mg/kg, and alendronate at 0.5 mg/kg orally, respectively. The seventh lumbar vertebrae were subjected to analysis of the preferential BAp c-axis orientation in the ventral cortical bone. The BAp c-axis orientation along the craniocaudal axis was significantly increased in the OVX monkeys. The high dose of minodronic acid suppressed the OVX-induced increase in the BAp c-axis orientation, whereas alendronate showed a non-significant tendency to suppress the increase in the orientation. In analysis with other parameters, the BAp c-axis orientation was positively correlated with bone formation indices in biochemical markers and bone histomorphometry and negatively correlated with the increase in lumbar bone mineral density. On the other hand, the BAp c-axis orientation was not correlated with bone resorption indices, except for the eroded surface. These results indicate that the increase in BAp c-axis orientation was ameliorated by minodronic acid treatment in OVX monkeys, mainly by suppression of bone formation increase.
Literatur
1.
Zurück zum Zitat Osteoporosis Prevention, Diagnosis, and Therapy (2001) NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef Osteoporosis Prevention, Diagnosis, and Therapy (2001) NIH consensus development panel on osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRef
2.
Zurück zum Zitat Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 8:2018–2026CrossRef Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 8:2018–2026CrossRef
4.
Zurück zum Zitat Ohno K, Mori K, Orita M, Takeuchi M (2011) Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem 18:220–233CrossRefPubMedPubMedCentral Ohno K, Mori K, Orita M, Takeuchi M (2011) Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase. Curr Med Chem 18:220–233CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44:1078–1084CrossRefPubMed Hagino H, Nishizawa Y, Sone T, Morii H, Taketani Y, Nakamura T, Itabashi A, Mizunuma H, Ohashi Y, Shiraki M, Minamide T, Matsumoto T (2009) A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. Bone 44:1078–1084CrossRefPubMed
6.
Zurück zum Zitat Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T (2012) Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 23:1737–1745CrossRefPubMedPubMedCentral Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T (2012) Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 23:1737–1745CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439–446CrossRefPubMedPubMedCentral Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Ohashi Y, Nakamura T, Matsumoto T (2012) Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30:439–446CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Tanaka M, Mori H, Kayasuga R, Ochi Y, Kawada N, Yamada H, Kishikawa K (2008) Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone 43:894–900CrossRefPubMed Tanaka M, Mori H, Kayasuga R, Ochi Y, Kawada N, Yamada H, Kishikawa K (2008) Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia. Bone 43:894–900CrossRefPubMed
9.
Zurück zum Zitat Mori H, Tanaka M, Kayasuga R, Masuda T, Ochi Y, Yamada H, Kishikawa K, Ito M, Nakamura T (2008) Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 43:840–848CrossRefPubMed Mori H, Tanaka M, Kayasuga R, Masuda T, Ochi Y, Yamada H, Kishikawa K, Ito M, Nakamura T (2008) Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 43:840–848CrossRefPubMed
10.
Zurück zum Zitat Burr D (1992) Estimated intracortical bone turnover in the femur of growing macaques: implications for their use as models for skeletal pathology. Anat Rec 232:180–189CrossRefPubMed Burr D (1992) Estimated intracortical bone turnover in the femur of growing macaques: implications for their use as models for skeletal pathology. Anat Rec 232:180–189CrossRefPubMed
11.
Zurück zum Zitat Jerome CP, Turner CH, Lees CJ (1997) Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis). Calcif Tissue Int 60:265–270CrossRefPubMed Jerome CP, Turner CH, Lees CJ (1997) Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis). Calcif Tissue Int 60:265–270CrossRefPubMed
12.
13.
Zurück zum Zitat Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS (2011) Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49:151–161CrossRefPubMed Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS (2011) Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 49:151–161CrossRefPubMed
14.
Zurück zum Zitat Jerome C, Missbach M, Gamse R (2012) Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 23:339–349CrossRefPubMed Jerome C, Missbach M, Gamse R (2012) Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 23:339–349CrossRefPubMed
15.
Zurück zum Zitat Smith SY, Recker RR, Hannan M, Müller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45–55CrossRefPubMed Smith SY, Recker RR, Hannan M, Müller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45–55CrossRefPubMed
16.
Zurück zum Zitat Itoh F, Kojima M, Furihata-Komatsu H, Aoyagi S, Kusama H, Komatsu H, Nakamura T (2002) Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate. J Bone Miner Res 17:534–543CrossRefPubMed Itoh F, Kojima M, Furihata-Komatsu H, Aoyagi S, Kusama H, Komatsu H, Nakamura T (2002) Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate. J Bone Miner Res 17:534–543CrossRefPubMed
17.
Zurück zum Zitat Nightingale JP, Lewis D (1971) Pole figures of the orientation of apatite in bones. Nature 232:334–335CrossRefPubMed Nightingale JP, Lewis D (1971) Pole figures of the orientation of apatite in bones. Nature 232:334–335CrossRefPubMed
18.
Zurück zum Zitat Landis WJ (1995) The strength of a calcified tissue depends in part on the molecular structure and organization of its constituent mineral crystals in their organic matrix. Bone 16:533–544CrossRefPubMed Landis WJ (1995) The strength of a calcified tissue depends in part on the molecular structure and organization of its constituent mineral crystals in their organic matrix. Bone 16:533–544CrossRefPubMed
19.
Zurück zum Zitat Sasaki N, Sudoh Y (1997) X-ray pole figure analysis of apatite crystals and collagen molecules in bone. Calcif Tissue Int 60:361–367CrossRefPubMed Sasaki N, Sudoh Y (1997) X-ray pole figure analysis of apatite crystals and collagen molecules in bone. Calcif Tissue Int 60:361–367CrossRefPubMed
20.
Zurück zum Zitat Elliot JC (1994) Structure and chemistry of the apatites and other calcium orthophosphates, 1st edn. Elsevier Science, Amsterdam Elliot JC (1994) Structure and chemistry of the apatites and other calcium orthophosphates, 1st edn. Elsevier Science, Amsterdam
21.
Zurück zum Zitat Nakano T, Kaibara K, Tabata Y, Nagata N, Enomoto S, Marukawa E, Umakoshi Y (2002) Unique alignment and texture of biological apatite crystallites in typical calcified tissues analyzed by microbeam X-ray diffractometer system. Bone 31:479–487CrossRefPubMed Nakano T, Kaibara K, Tabata Y, Nagata N, Enomoto S, Marukawa E, Umakoshi Y (2002) Unique alignment and texture of biological apatite crystallites in typical calcified tissues analyzed by microbeam X-ray diffractometer system. Bone 31:479–487CrossRefPubMed
22.
Zurück zum Zitat Ishimoto T, Nakano T, Umakoshi Y, Yamamoto M, Tabata Y (2013) Degree of biological apatite c-axis orientation rather than bone mineral density controls mechanical function in bone regenerated using recombinant bone morphogenetic protein-2. J Bone Miner Res 28:1170–1179CrossRefPubMed Ishimoto T, Nakano T, Umakoshi Y, Yamamoto M, Tabata Y (2013) Degree of biological apatite c-axis orientation rather than bone mineral density controls mechanical function in bone regenerated using recombinant bone morphogenetic protein-2. J Bone Miner Res 28:1170–1179CrossRefPubMed
23.
Zurück zum Zitat Nakano T, Kaibara K, Ishimoto T, Tabata Y, Umakoshi Y (2012) Biologicalapatite (BAp) crystallographic orientation and texture as a new index for assessing the microstructure and function of bone regenerated by tissue engineering. Bone 51:741–747CrossRefPubMed Nakano T, Kaibara K, Ishimoto T, Tabata Y, Umakoshi Y (2012) Biologicalapatite (BAp) crystallographic orientation and texture as a new index for assessing the microstructure and function of bone regenerated by tissue engineering. Bone 51:741–747CrossRefPubMed
24.
Zurück zum Zitat Shiraishi A, Miyabe S, Nakano T, Umakoshi Y, Ito M, Mihara M (2009) The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet Disord 10:66CrossRefPubMedPubMedCentral Shiraishi A, Miyabe S, Nakano T, Umakoshi Y, Ito M, Mihara M (2009) The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet Disord 10:66CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Yoshida Y, Moriya A, Kitamura K, Inazu M, Okimoto N, Okazaki Y, Nakamura T (1998) Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res 13:1011–1022CrossRefPubMed Yoshida Y, Moriya A, Kitamura K, Inazu M, Okimoto N, Okazaki Y, Nakamura T (1998) Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction. J Bone Miner Res 13:1011–1022CrossRefPubMed
26.
Zurück zum Zitat Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D (1993) The effects of 2-year treatment with the amino bisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577–2586CrossRefPubMedPubMedCentral Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D (1993) The effects of 2-year treatment with the amino bisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577–2586CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Noyama Y, Nakano T, Ishimoto T, Sakai T, Yoshikawa H (2013) Design and optimization of the oriented groove on the hip implant surface to promote bone microstructure integrity. Bone 52:659–667CrossRefPubMed Noyama Y, Nakano T, Ishimoto T, Sakai T, Yoshikawa H (2013) Design and optimization of the oriented groove on the hip implant surface to promote bone microstructure integrity. Bone 52:659–667CrossRefPubMed
28.
Zurück zum Zitat Müller R, Hannan M, Smith SY, Bauss F (2004) Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 19:1787–1796CrossRefPubMed Müller R, Hannan M, Smith SY, Bauss F (2004) Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res 19:1787–1796CrossRefPubMed
29.
Zurück zum Zitat Yamagami Y, Mashiba T, Iwata K, Tanaka M, Nozaki K, Yamamoto T (2013) Effects of minodronic acid and alendronate on bone remodeling, micro damage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys. Bone 54:1–7CrossRefPubMed Yamagami Y, Mashiba T, Iwata K, Tanaka M, Nozaki K, Yamamoto T (2013) Effects of minodronic acid and alendronate on bone remodeling, micro damage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys. Bone 54:1–7CrossRefPubMed
30.
Zurück zum Zitat Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20–33CrossRefPubMed Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49:20–33CrossRefPubMed
Metadaten
Titel
Evaluation of crystallographic orientation of biological apatite in vertebral cortical bone in ovariectomized cynomolgus monkeys treated with minodronic acid and alendronate
verfasst von
Makoto Tanaka
Aira Matsugaki
Takuya Ishimoto
Takayoshi Nakano
Publikationsdatum
01.03.2016
Verlag
Springer Japan
Erschienen in
Journal of Bone and Mineral Metabolism / Ausgabe 2/2016
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-015-0658-2

Weitere Artikel der Ausgabe 2/2016

Journal of Bone and Mineral Metabolism 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.